Outcomes of 3,737 COVID-19 patients treated with Hydroxychloroquine & Azithromycin and other regimens in Marseille, France: A retrospective analysis
“In our institute in Marseille, France, we initiated early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with Hydroxychloroquine and Azithromycin (HCQ-AZ) was proposed for the positive cases.”
“We retrospectively report the clinical management of 3,737 screened patients, including 3,119 (83.5%) treated with HCQ-AZ (200 mg of oral HCQ, three times daily for ten days and 500 mg of oral AZ on day 1 followed by 250 mg daily for the next four days, respectively) for at least three days”
“Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days (odds ratios 95% CI 0.38 0.27–0.54) and shorter duration of viral shedding (time to negative PCR: HR 1.29 1.17–1.42)
“early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.”
“[For patients given HCQ] QTc prolongation (>60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 12 cases including 3 cases with QTc> 500 ms. No cases of torsade de pointe or sudden death were observed.”
“No cases of torsade de pointe or sudden death were observed.”
“However, the choice of the best treatment should be made according to its safety profile, which is much better for HCQ-AZ than for Remdesivir (adverse events leading to cessation of treatment in 0.9% in our study vs. 12% for Remdesivir.”
“Nevertheless, we were surprised by the large discrepancy on efficacy and toxicity of HCQ in recent studies compared to ours.” (A very benign way of saying the other studies are nothing of lies)
“Excellent safety profile of HCQ-AZ in our real-life medical experience much better reflects the reality than registry studies such as those recently retracted from high profile medical journals.”
“Including remdesivir and hyperimmune gamma globulins, may have antiviral activity at an early stage of the disease, although there is to date no convincing published report, comparable to that of oseltamivir at the early stage of influenza.” Remdesivir DOES NOT WORK!
“Zinc supplementation should be also considered, as recently reported”
This deserves repeating: “However, the choice of the best treatment should be made according to its safety profile, which is much better for HCQ-AZ than for remdesivir” 
“HCQ-AZ ≥3 days was an independent protective factor against death and/or transfer to ICU”
“Finally, the significant association between treatment with HCQ-AZ≥3days and reduction of risk of death was confirmed to be independent of age, comorbidities and severity of the disease, by two different propensity score methods.”
“Adverse events were observed in 167 (4.5%) patients. All adverse events were mild and included mostly gastrointestinal symptoms.”
“We paid specific attention to QTc prolongation, which was observed (>60 ms) in 25 patients (0.67%), including 2 treated with HCQ (2%), 3 treated with AZ (2.2%) and 20 treated with HCQ-AZ (0.6%)”
This also deserves repeating and I will end it here:
No cases of torsade de pointe or sudden death were observed.
https://www.sciencedirect.com/science/article/pii/S1477893920302817